SPOTLIGHT -
Reflector is Pharm Exec's Brussels correspondent.
Competing European Bids to Fund New Antibiotics
Uncertainty swirls on just how effective policy competition between the EU and UK on these much-needed products will be.
Do Findings Point to a Tarnished COVID Victory for Europe?
Report on lessons from crisis includes—and ignites—some criticism.
Contrasting Aims Highlight Pharma Reform Pursuits
Some new EU plans "fly in the face" of innovation, critics contend.
New EU Proposals to Regulate Pharma Duck the Difficult Questions
Advancing the concept of "health competencies" remains elusive.
Europe’s Drug Pricing Conundrums Coming to a Head
More opinions enter the mix as EU launches legislation review.
European Policy Called Out as Threat to Drug Trade and Investment
US pharma industry handcuffed by restrictions, group argues.
The Challenge of Taking on Falsified Medicines in Europe
Region’s diversity plays against efforts to curtail counterfeit drugs.
Interpreting the Message of Europe’s New Health ‘Vision’
Is agenda blurring the line between alliances and assimilation?
Vaccine Surpluses Drive Acrimonious European Debates
Member states air concerns over excess supplies of COVID vaccines.
Seeking Concrete Solutions to Europe’s Supply Problems
No shortage of views being expressed on drug shortages.
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?
Making sense of surprise rejection of draft proposals.
Push for Full Embrace of Digital Care Draws Opposition in Europe
Patient safety and data protection concerns highlight hesitancy.
How Much Data Does Pharma Want to Share?
And, in equal measure, patients and doctors—as EU mulls new rules.
Optimism Abounds On New EU Blood And Tissue Rules
Proposed SoHO reform elicits wide support, but risks acknowledged.
Rewriting European Regulations on Rare Disease Treatments
Legislative-reform alliance makes for strange bedfellows.
A Storm in a Brussels Teacup Could Threaten Drug-Pricing Waters
Group’s ideas to change EU pricing rules draw captive audience.
Can Pharma Seize the High Ground in Latest Pricing Proposal Flurry?
The risky business of outmaneuvering Europe’s drug pricing authorities.
Europe’s New HTA System Spurs More Debate, Concern
Fresh round of discussions around health technology assessment.
Aligning the Many Interpretations of ‘Unmet Medical Need’
Efforts for a standardized approach coming to a head in Europe.
EU Steps in on Pricing, Offers Member States Aid to Negotiate
European Commission looks to relieve issues without legislation.
Europe Searches for Better Collaboration Across Regulators
Looks to address disconnect between registration and reimbursement.
IP and Pharmaceutical Trade: Europe’s Unresolved Debate
Lack of IP management plagues recent regulatory discussions.
EU MEPs Arrive At Crossroads in Cancer Strategy
Committee struggles to find a common treatment approach.
A FAB Opportunity Emerging for Europe’s Drugmakers
New EU initiative aims to curve shortage of vaccines and therapies.
Advanced Therapy Makers Claim a Double Barrier Over Access
Treatment availability for rare disease patients under fire in Europe.
Contention Swirls Around COVID Patent Waivers
Report claims an imbalance in influence of tech-transfer decisions.
COVID Blame Games Give Way to Lesson Learning
Summits, proposals outline advice on response to future pandemics.
Bringing a European Focus to Drug Import Vulnerabilities
Pandemic triggers urgency around supply chain initiatives.
What’s to Come for HTA Legislation and Collaboration?
The progress and stumbling blocks in building a formal EU system.
Long-View Innovation Hopes for Pharma Policy in the EU
Draft plan looks beyond the immediate European health challenges.